Actinium Pharmaceuticals, Inc - ATNM STOCK NEWS

Actinium Pharmaceuticals presented data from the Phase 3 SIERRA trial of Iomab-B at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

Iomab-B, a CD45 targeting ARC, significantly improved survival for high-risk relapsed or refractory AML patients, including those with TP53 mutations. The trial achieved its primary endpoint of durable Complete Remission with high statistical significance (p<0.0001). Patients receiving Iomab-B had a median OS of 5.49 months compared to 1.66 months for the control group.

Actinium also showcased its novel linker technology, demonstrating high tumor uptake and in vivo stability in preclinical models, with significantly lower kidney and liver uptake compared to standard DOTA linkers. This technology supports the expansion of Actinium's ARC pipeline for solid tumors.

The SIERRA trial involved 153 patients, with Iomab-B delivering targeted radiation more effectively and safely than total body irradiation, while sparing healthy organs.

Actinium has two U.S. patents for its linker technology extending into 2043, with a pending international application.

Actinium Pharmaceuticals will host a KOL webinar on May 20, 2024, at 8:00 AM ET to discuss the Iomab-ACT commercial CAR T-cell therapy trial being conducted at the University of Texas Southwestern (UTSW). Dr. Farrukh Awan, an expert in leukemia and lymphoma treatment, will join as the principal investigator. Iomab-ACT, an ARC targeting CD45, aims to replace non-targeted chemotherapy in conditioning prior to cell and gene therapies. Phase 1 trial results showed no immune effector cell-associated neurotoxicity syndrome (ICANS) in treated patients and minimal Cytokine Release Syndrome (CRS). The CAR-T market, projected to grow at an 11% CAGR, presents a significant opportunity for Iomab-ACT, which targets an addressable patient population expected to reach 93,000 in the U.S. by 2030.

Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients with relapsed or refractory acute myeloid leukemia (r/r AML) receiving an Iomab-B led bone marrow transplant (BMT). Patients with TP53 mutations saw a median overall survival of 5.49 months compared to 1.66 months for those not receiving Iomab-B. The trial enrolled high-risk patients and showed 92% 1-year survival and 69% 2-year survival rates in those receiving Iomab-B led BMT.

Actinium Pharmaceuticals announced that multiple abstracts highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A, along with novel linker technology for solid tumors, have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting. The abstracts feature improved survival with both Iomab-B and Actimab-A in high-risk acute myeloid leukemia patients, including TP53 mutations. Actinium's presence at the SNMMI showcases its leadership in developing ARCs, with a focus on targeted radiotherapy for blood cancers and solid tumors.

Actinium Pharmaceuticals, Inc. announced a KOL webinar to discuss its Iomab-ACT trial with a leading FDA approved CAR T-cell therapy at the University of Texas Southwestern. The webinar will highlight the potential billion-dollar market opportunity in lymphodepletion. Dr. Farrukh Awan will lead the trial, aiming to study Iomab-ACT with an FDA approved CAR-T cell therapy for the first time. The company presented positive phase 1 trial results at the Tandem Meetings, showing promising safety and efficacy profiles. With the expanding CAR-T market and the need for improved conditioning in cellular therapy, Iomab-ACT presents a revenue opportunity in line with the growing patient population for cell and gene therapies.

Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B at the European Bone Marrow Transplant Annual Meeting, showing higher remission rates and durable complete remission in patients with active relapsed or refractory acute myeloid leukemia. The study revealed a median overall survival of 5.49 months in TP53 positive patients receiving Iomab-B, compared to 1.66 months in those who did not receive it.

Actinium Pharmaceuticals, Inc. announces positive Phase 3 SIERRA trial results for Iomab-B in patients with TP53 mutation at the European Bone Marrow Transplant Society meeting. The trial showed high statistical significance in achieving durable Complete Remission and 100% BMT access.

Actinium Pharmaceuticals, Inc. announces a potential breakthrough in targeted radiotherapy conditioning with Iomab-ACT, aiming to replace non-targeted chemotherapy in cell and gene therapies. The collaboration with UT Southwestern for a clinical trial on CAR T-cell therapy shows promising results in reducing toxicities like ICANS and CRS. Iomab-ACT presents a significant market opportunity in the growing field of cellular and gene therapies.

Actinium Pharmaceuticals, Inc. announces a strategic initiative to manufacture Actinium-225 using a proprietary cyclotron-based method. The company's technology is supported by 5 U.S. patents, 49 international patents, and significant technical expertise. Actinium-225 produced by this method is highly pure, cost-effective, and has higher yields. The initiative includes a multi-million-dollar investment to scale up production to meet growing demand. Actinium aims to collaborate globally to maximize the value of its patents and capabilities.